LDS/Medical Tests/VENTANA® MET (SP44) RxDx IHC Assay for non-squamous, non-small cell lung cancer (NSQ-NSCLC)

VENTANA® MET (SP44) RxDx IHC Assay for non-squamous, non-small cell lung cancer (NSQ-NSCLC)

Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of cancer-related death worldwide in both men and women. NSCLC represents approximately 80-85% of all new lung cancer cases. Patients diagnosed with advanced NSCLC often face a poor prognosis, with median survival of less than one year. The VENTANA MET (SP44) RxDx Assay is the first FDA-approved immunohistochemistry (IHC) assay to identify patients with non-squamous, non-small cell lung cancer (NSQ-NSCLC) who are eligible for MET-targeted treatment with Emrelis™ (telisotizumab vedotin).

MET (also called tyrosine-protein kinase MET or c-MET) is a heterodimeric receptor tyrosine kinase encoded by the MET proto-oncogene located on chromosome 7q21-q31 and is expressed on the surface of various epithelial cells, which makes the MET protein an actionable target for antibody drug conjugates (ADCs). MET serves as a predictive biomarker for the likelihood of response to MET-targeted therapy for patients with NSCLC. Furthermore, MET protein overexpression is found in approximately 25% of advanced EGFR wild-type NSQ-NSCLC patients and is often associated with poor prognosis.

VENTANA MET (SP44) RxDx Assay uses rabbit monoclonal anti-MET antibody (clone SP44) for stating. The staining in NSQ-NSCLC exhibits a membranous and/or cytoplasmic pattern. The staining signal intensity is classified as strong, moderate, weak, or negative based on membranous and/or cytoplasmic localization. In NSQ-NSCLC, tumor cells stained with VENTANA MET (SP44) RxDx Assay are evaluated for percentage of tumor cells exhibiting strong (3+) intensity. Strong staining intensity is characterized by dark brown to black staining of the membranes and/or cytoplasm. Strong staining membranes and/or cytoplasm are easily detectable at low power magnifications such as 2x or 4x. NSQ-NSCLC tissue cases are considered positive for MET status if ≥ 50% of viable tumor cells demonstrate strong membranous and/or cytoplasmic staining. MET overexpression by IHC is considered a predictive biomarker for response to MET-targeted therapy. In the LUMINOSITY trial, patients selected by this assay who had MET overexpression and received Emrelis showed measurable clinical responses and a median duration of response of 7.2 months.

  • As an aid in identifying NSQ-NSCLC patients who may be eligible for treatment with Emrelis™ (telisotuzumab vedotin)
  • Companion diagnostic for therapy selection and therapeutic planning based on MET expression status

Positive (MET overexpression): ≥50% of viable tumor cells with strong (3+) membrane and/or cytoplasmic staining. Patients may be eligible for MET-targeted therapy (Emrelis).

Negative (MET low / not overexpressed): <50% of cells show strong staining; not classified as MET overexpression and likely ineligible for therapy under current indication. Not Evaluable (N/E): Insufficient tumor content, poor tissue quality, artifacts, or technical issues that prevent reliable interpretation.

Immunohistochemistry (IHC) using the rabbit monoclonal anti-MET SP44 antibody, with detection via the OptiView DAB IHC detection system on BenchMark ULTRA / ULTRA PLUS instruments.

Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue, including biopsies, resections, or cell block preparations.

Stability

FFPE is stable at room temperature for longer.

Molecular testing for MET amplification, exon 14 skipping, or MET gene rearrangements, Next-generation sequencing (NGS) panels covering lung cancer driver genes, PD-L1 IHC, EGFR, ALK, ROS1, BRAF testing for comprehensive NSCLC molecular profiling.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Clin Oncol. 2024 Sep 1;42(25):3000-3011. [PMID: 38843488]
  • Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48. [PMID: 21102609]
  • Clin Cancer Res. 2017 Feb 15;23(4):992-1000. [PMID: 27573171]
  • Onco Targets Ther. 2020 Mar 25;13:2491-2510. [PMID: 32273721]
  • Roche. VENTANA MET (SP44) RxDx Assay, US Package Insert. 2025.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login